Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming,Journal of Neuroimmunology

当前位置： X-MOL 学术 › J. Neuroimmunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Guillain-Barré Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming
Journal of Neuroimmunology ( IF 2.9 ) Pub Date : 2020-09-01 , DOI: 10.1016/j.jneuroim.2020.577267
Catherine Maurice ₁ , Leila Khoja ₂ , Erin Morgan ₃ , Warren P Mason ₁ , Hans Katzberg ₄ , Austin M Pereira ₅ , Amanda Pereira ₆ , Marcus Butler ₇

Affiliation

Over the past two decades, there has been a fundamental shift away from traditional cytotoxic chemotherapy towards the identification, and subsequent suppression of specific oncogenes. Immunotherapy and targeted therapy prime the immune system, potentially leading to deleterious side effects. The following case of Guillain-Barré Syndrome (GBS) emphasizes the importance of considering every agent when iatrogenic toxicity is suspected. We underline the possibility of immune priming by checkpoint inhibitors. An optimal understanding of the pathogenesis and toxicity of targeted therapy is key in an era where the prognosis of melanoma is revolutionized by the use of novel agents. Our case emphasizes the importance of considering every agent in the context of toxicity induced by combined novel therapies.

中文翻译：

格林-巴利综合症继一系列适应免疫启动时代黄金标准的新疗法之后

在过去的二十年中，从传统的细胞毒性化疗转向特定癌基因的识别和随后的抑制发生了根本性的转变。免疫疗法和靶向疗法可以增强免疫系统，可能导致有害的副作用。以下吉兰-巴利综合征 (GBS) 病例强调了在怀疑医源性毒性时考虑每种药物的重要性。我们强调检查点抑制剂启动免疫的可能性。在新药的使用彻底改变黑色素瘤预后的时代，对靶向治疗的发病机制和毒性的最佳理解是关键。我们的案例强调了在联合新疗法引起的毒性背景下考虑每种药物的重要性。

更新日期：2020-09-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11